A new polymorphism in the coding region of exon four in HSD17B2 in relation to risk of sporadic and hereditary breast cancer

Breast Cancer Research and Treatment

Volumn 106, Issue 1, 2007, Pages 57-64

  Jansson, Agneta ^a   Carlsson, Jonas ^a   Olsson, Anette ^a   Storm, Petter ^a   Margolin, Sara ^b   Gunnarsson, Cecilia ^a   Stenmark Askmalm, Marie ^a   Lindblom, Annika ^c   Persson, Bengt ^a   Stål, Olle ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Breast cancer; HSD17B2; Intracrinology; Oestradiol; Polymorphism

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; METHIONINE DERIVATIVE; STEROID; TESTOSTERONE 17BETA DEHYDROGENASE; VALINE;

ADULT; AGED; ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ENZYME BINDING; EXON; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATALYTIC DOMAIN; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; ESTRADIOL DEHYDROGENASES; EXONS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MODELS, MOLECULAR; PEDIGREE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEIN CONFORMATION; RISK ASSESSMENT; RISK FACTORS;

EID: 34848829864     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9477-4     Document Type: Article

References (35)

1. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Belanger A (2000) Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 25:1-16
2. Vermeulen A, Deslypere JP, Paridaens R, Leclercq G, Roy F, Heuson JC (1986) Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 122:515-525
3. Bonney RC, Reed MJ, Davidson K, Beranek PA, James VH (1983) The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocrinol (Oxf) 19:727-739
4. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45:2900-2906
5. Yue W, Wang JP, Hamilton CJ, Demers LM, Santen JR (1998) In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 58:927-932
6. Pasqualini JR (2004) The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 1654:123-143
7. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Belanger A (1997) The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62:148-158
8. Vihko P, Isomaa V, Gosh D (2001) Structure and function of 17 beta-hydroxysteroid dehydrogenase type 1 and type 2. Mol Cell Endocrinol 171:71-76
9. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB, Atkin SL (1998) Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer 78:1421-1429
10. Gunnarsson C, Olsson BM, Stal O (2001) Southeast Sweden breast cancer group: abnormal expression of 17 beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Res 61:8448-8851
11. Gunnarsson C, Hellqvist E, Stal O (2005) 17 beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br J Cancer 92:547-552
12. Oduwole OO, Li Y, Isomaa VV, Mantyniemi A, Pulkka AE, Soini Y, Vihko PT (2004) 17 beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 64:7604-7609
13. Oduwole OO, Isomaa VV, Nokelainen PA, Stenback F, Vihko PT (2002) Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development. Int J Cancer 97:1-6
14. Koh E, Noda T, Kanaya J, Namiki M (2002) Differential expression of 17 beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53:154-159
15. Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B, Nordenskjold B,. Rutqvist LE, Skoog L, Stal O (2003) Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22:34-40
16. Wu L, Einstein M, Geissler WM, Chan HK, Elliston KO, Andersson S (1993) Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem 268:12964-12969
17. Cleton-Jansen AM, Moerland EW, Kuipers-Dijkshoorn NJ, Callen DF, Sutherland GR, Hansen B, Devilee P, Cornelisse CJ (1994) At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer 9:101-107
18. Lindblom A, Rotstein S, Skoog L, Nordenskjold M, Larsson C (1993) Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res 53:3707-3711
19. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, Vihko R, Vihko P (1997) Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res 57:3356-3359
20. Cleton-Jansen AM, Callen DF, Seshadri R, Goldup S, Mccallum B, Crawford J, Powell JA, Settasatian C, van Beerendonk H, Moerland EW, Smit VT, Harris WH, Millis R, Morgan NV, Barnes D, Mathew CG, Cornelisse CJ (2001) Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Res 61:1171-1177
21. Margolin S, Werelius B, Fornander T, Lindblom A (2004) BRCA1 mutations in a population-based study of breast cancer in Stockholm County. Genet Test 2:127-32
22. Abagyan RA, Totrov MM, Kuznetsov DN (1994) ICM-a new method for protein modeling and design. Applications to docking and structure prediction from the distorted native conformation. J Comp Chem. 15:488-506
23. Nemethy G, Gibson KD, Palmer KA, Yoon CN, Paterlini G, Zagari A, Rumsey S, Scheraga HA (1992) Energy Parameters in Polypeptides. 10. Improved geometric parameters and nonbonded interactions for use in the ECEPP/3 algorithm, with application to proline-containing peptides. J Phys Chem 96:6472-6484
24. Fernandez-Recio J, Totrov M, Abagyan R (2003) ICM-DISCO Docking by Global Energy Optimization with Fully Flexible Side-Chains. Proteins 52:113-117
25. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389-3402
26. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LS (2005) The Universal Protein Resource (UniProt). Nucleic Acids Res 33:D154-159
27. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680
28. Kyte J, Doolittle RF (1982) A, simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132
29. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ (2004) De Vivo I.HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 13:213-219
30. Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burtt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D (2006) Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res 66:2468-2475
31. Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burtt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Le Marchand L, Ma J, Overvad K, Palli D, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S (2005) Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet 1:e68
32. Zhou XL, Werelius B, Lindblom A (2004) A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer. Breast Cancer Res 6:187-190
33. van Wezel T, Lombaerts M, van Roon EH, Philippo K, Baelde HJ, Szuhai K, Cornelisse CJ, Cleton-Jansen AM (2005) Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res 7:998-1004
34. Whitmore SA, Settasatian C, Crawford J, Lower KM, McCallum B, Seshadri R, Cornelisse CJ, Moerland EW, Cleton-Jansen AM, Tipping AJ, Mathew CG, Savnio M, Savoia A, Verlander P, Auerbach AD, Van Berkel C, Pronk JC, Doggett NA, Callen DF (1998) Characterization and screening for mutations of the growth arrest-specific 11 (GAS11) and C16orf3 genes at 16q24.3 in breast cancer. Genomics 52:325-331
35. Cleton-Jansen AM, Moerland EW, Pronk JC, van Berkel CG, Apostolou S, Crawford J, Savoia A, Auerbach AD, Mathew CG, Callen DF, Cornelisse C (1999) Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3. Br J Cancer 79:1049-1052